JW Pharmaceutical announced on the 31st that its operating profit for the second quarter on a separate basis was 25.4 billion won, an increase of 103.3% compared to the same period last year. Revenue rose to 189.7 billion won, an 11.2% increase over the same period.
However, the company noted that a temporary shift to a loss occurred due to the impact of tax penalties from a regular tax audit.
According to the company, revenue in the second quarter from the institutional sector of prescription drugs increased by 13.3% year on year to 156.3 billion won, driving overall performance. During the same period, revenue from the dyslipidemia treatment 'Rivaroxaban' increased by 35.3% to 25.4 billion won, while the 'Rivaroxaban family' (Rivaroxaban·Rivarojet·Rivarobvi) increased by 18.4% to 47.4 billion won.
Sales of the hemophilia treatment 'Hemlibra' reached 15.3 billion won, a 24% increase compared to the same period last year. The rheumatoid arthritis treatment 'Actemra' increased by 0.5% to 6.5 billion won.
Sales of the high-dose iron injection 'Ferrinject', which was applied to health insurance benefits in May last year, increased by 92.4% over the same period last year to 4.3 billion won. The intravenous solution sector grew by 2.3% to 61.8 billion won compared to the same period last year.
A representative of JW Pharmaceutical said, 'The focus on a portfolio centered on prescription drugs and the growth of high-value products have led to improved performance,' and added, 'In the second half, we will continue stable growth based on the competitiveness of original pharmaceuticals.'